Esomeprazole (Nexium)

The S-isomer of omeprazole.

Also Known As:

Nexium; Esomeprazole Magnesium; Esomeprazole Potassium; Esomeprazole Sodium; Esomeprazole Strontium; Esomeprazole Strontium Anhydrous; Strontium, Esomeprazole; 5-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole

Networked: 789 relevant articles (166 outcomes, 263 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Illueca, Marta: 20 articles (07/2015 - 03/2006)
2.	Traxler, Barry: 14 articles (01/2018 - 08/2004)
3.	Tolia, Vasundhara: 14 articles (07/2015 - 11/2007)
4.	Lind, T: 13 articles (05/2017 - 07/2000)
5.	Lind, Tore: 13 articles (08/2016 - 10/2004)
6.	Johnson, David A: 10 articles (11/2018 - 03/2002)
7.	Lundborg, Per: 10 articles (07/2015 - 03/2006)
8.	Lauritsen, K: 10 articles (10/2011 - 12/2000)
9.	Gilger, Mark A: 9 articles (07/2015 - 05/2008)
10.	Labenz, J: 9 articles (06/2009 - 12/2000)

Related Diseases

1.	Gastroesophageal Reflux (GERD) 07/01/2015 - "GERD symptom scores were significantly improved from baseline to the final week of the study in all of the treatment groups (P < 0.01) CONCLUSIONS:: In children ages 1 to 11 years with endoscopically proven GERD, esomeprazole (at daily doses of 5, 10, or 20 mg) was generally well tolerated. " 07/01/2015 - "GERD symptom scores were significantly improved from baseline to the final week of the study in all of the treatment groups (P < 0.01) CONCLUSIONS: In children ages 1 to 11 years with endoscopically proven GERD, esomeprazole (at daily doses of 5, 10, or 20 mg) was generally well tolerated. " 05/01/2008 - "GERD symptom scores were significantly improved from baseline to the final week of the study in all of the treatment groups (P < 0.01) In children ages 1 to 11 years with endoscopically proven GERD, esomeprazole (at daily doses of 5, 10, or 20 mg) was generally well tolerated. " 07/01/2015 - "To evaluate safety, tolerability, and symptom improvement with once-daily esomeprazole in children with endoscopically proven gastroesophageal reflux disease (GERD). " 07/01/2015 - "To evaluate safety, tolerability, and symptom improvement with once-daily esomeprazole in children with endoscopically proven gastroesophageal reflux disease (GERD). "
2.	Esophagitis 04/01/2002 - "Esomeprazole is effective in the healing of erosive esophagitis, with a rate of healing at week 8 of 93.7% (p < 0.001). " 01/01/2018 - "Phase II clinical trials showed that, compared with Esomeprazole, the new PPI Ilaparazole is great in terms of efficacy for reflux symptoms relief and curling for esophagitis. " 08/01/2004 - "Evidence-based assessment of the efficacy of esomeprazole for the healing of erosive esophagitis." 07/01/2015 - "Esomeprazole for the Treatment of Erosive Esophagitis in Children: An International, Multicenter, Randomized, Parallel-Group, Double-Blind (for Dose) Study." 07/01/2015 - "Esomeprazole for the Treatment of Erosive Esophagitis in Children: An International, Multicenter, Randomized, Parallel-Group, Double-Blind (for Dose) Study."
3.	Heartburn (Pyrosis) 05/01/2017 - "At week 2, the percentages of subjects who experienced complete heartburn resolution were significantly greater with esomeprazole 40 mg (study 1, 26.1%; study 2, 35.3%) and 20 mg (study 1, 25.2%; study 2, 35.7%) compared with placebo (study 1, 9.0%; study 2, 3.4%) (all, P ≤ 0.001). " 05/01/2017 - "Additionally, at week 2, the percentages of subjects experiencing heartburn relief were significantly greater with esomeprazole 40 mg (study 1, 35.3%; study 2, 40.5%) and 20 mg (study 1, 34.5%; study 2, 46.4%) compared with placebo (study 1, 16.5%; study 2, 8.6%) (all, P ≤ 0.001). " 05/01/2017 - "Beginning on day 1, the percentages of subjects who experienced sustained heartburn resolution was significantly greater in the groups treated with esomeprazole 40 mg (study 1, 19%; study 2, 19%; P < 0.0001) and 20 mg (study 1, 10%; study 2, 15%; P < 0.05) compared with the group that received placebo (study 1, 2%; study 2, 1%). " 01/01/2019 - "Change in the percentage of heartburn-free days from the run-in was significantly greater with esomeprazole compared with placebo (p<0.001) starting on days 1-4. The greatest treatment benefit was observed during days 5-14. " 07/01/2014 - "Within the first 4 days, the proportion of subjects with heartburn-free days was significantly greater with esomeprazole 20 mg versus placebo. "
4.	Infections 01/01/2020 - "Efficacy of Seven-day High-dose Esomeprazole-based Triple Therapy versus Seven-day Standard Dose Non-esomeprazole-based Triple Therapy as the First-line Treatment of Patients with Helicobacter pylori Infection." 11/01/2010 - "Esomeprazole magnesium as a monotherapy was evaluated vs triple therapy in patients with HP infection. " 09/01/2007 - "High-dose versus low-dose esomeprazole-based triple therapy for Helicobacter pylori infection." 06/01/2007 - "[Different courses of esomeprazole-based triple therapy for Helicobactor pylori infection in children]." 08/01/2006 - "Esomeprazole-based 1-week triple therapy directed by susceptibility testing for eradication of Helicobacter pylori infection in children."
5.	Ulcer 11/01/2005 - "In addition, the efficacy of esomeprazole for the healing and prevention of nonsteroidal anti-inflammatory drug-associated dyspeptic symptoms and ulcers has been established. " 10/21/2022 - "This study was aimed toward investigating whether an extended course of oral esomeprazole up to 1 year decreased ulcer rebleeding in such patients. " 05/01/2019 - "Dose-related healing of artificial ulcers after endoscopic submucosal dissection using esomeprazole: A randomized controlled study." 04/01/2006 - "In the VENUS study, the life table estimated proportion of patients who developed ulcers over 6 months (primary variable, intent-to-treat population) was 20.4% on placebo, 5.3% on esomeprazole 20 mg (p < 0.001), and 4.7% on esomeprazole 40 mg (p < 0.0001). " 10/21/2022 - "An extended 36-week course of oral esomeprazole 20 mg, twice- or once-daily for patients with Rockall scores ≥6 reduced ulcer rebleeding during the first year, but the effect needed to be further validated when PPIs were shifted to on-demand or discontinued thereafter (NCT02456012, 28/05/2015)."

Related Drugs and Biologics

1.	Omeprazole (Prilosec)
2.	Pantoprazole (Protonix)
3.	Proton Pump Inhibitors
4.	Acids
5.	Lansoprazole (Prevacid)
6.	Naproxen (Naprosyn)
7.	Aspirin (Acetylsalicylic Acid)
8.	Rabeprazole (Aciphex)
9.	Amoxicillin (Wymox)
10.	Clopidogrel (Plavix)

Related Therapies and Procedures

1.	Therapeutics
2.	Fundoplication
3.	Endoscopic Hemostasis
4.	Intravenous Infusions
5.	Chemoprevention